EconPapers    
Economics at your fingertips  
 

The Use of Genetic Testing Information in the Insurance Industry: An Ethical and Societal Analysis of Public Policy Options

Alexander Nill (), Gene Laczniak () and Paul Thistle ()
Additional contact information
Alexander Nill: University of Nevada Las Vegas
Gene Laczniak: Marquette University
Paul Thistle: University of Nevada Las Vegas

Journal of Business Ethics, 2019, vol. 156, issue 1, No 9, 105-121

Abstract: Abstract Informed by a search of the literature about the usage of genetic testing information (GTI) by insurance companies, this paper presents a practical ethical analysis of several distinct public policy options that might be used to govern or constrain GTI usage by insurance providers. As medical research advances and the extension to the Human Genome Project (2016, https://en.wikipedia.org/wiki/Human_Genome_Project_-_Write ) moves to its fullness over the next decade, such research efforts will allow the full synthesis of human DNA to be connected to predictive health dispositions. As testing costs fall, there will be ever more pressure for citizens to disclose GTI. Genetic testing information is integral to future medical care because it can be used to better assess individually tailored medical therapies as well as to allow a more informed risk analysis by the insurance industry, which in some countries such as the USA underwrites a majority of citizen medical expenses. As discussed in this examination, the revelation of people’s uniquely personal GTI to insurers has enormous societal implications. The major contribution of the paper is to offer policy makers and concerned citizens a nuanced articulation of the basic options to regulate GTI, with a special consideration for ethical fairness and equity. As genetic-based medicine blossoms and pressures to reduce healthcare costs increase, there will be an ever greater impetus for countries to revisit their genetic testing policies. Organizations and policy makers striving to create GTI oversights perceived to be both “fair and effective” need to be aware of the ethical perspectives discussed in this paper.

Keywords: Genetic testing; Health insurance; Healthcare ethics; Discrimination; Applied ethics; Distributive justice; Health information privacy (search for similar items in EconPapers)
Date: 2019
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
http://link.springer.com/10.1007/s10551-017-3554-y Abstract (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:kap:jbuset:v:156:y:2019:i:1:d:10.1007_s10551-017-3554-y

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10551/PS2

DOI: 10.1007/s10551-017-3554-y

Access Statistics for this article

Journal of Business Ethics is currently edited by Michelle Greenwood and R. Edward Freeman

More articles in Journal of Business Ethics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2025-03-19
Handle: RePEc:kap:jbuset:v:156:y:2019:i:1:d:10.1007_s10551-017-3554-y